Satoshi Matsuo1, Yuriko Saiki2, Osamu Adachi1, Shunsuke Kawamoto1, Shinichi Fukushige2, Akira Horii2, Yoshikatsu Saiki3. 1. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. 2. Department of Molecular Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan. 3. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: yoshisaiki@med.tohoku.ac.jp.
Abstract
OBJECTIVE: Lung ischemia-reperfusion (IR) injury during cardiopulmonary surgery is associated with postoperative morbidity and mortality, particularly in patients with pulmonary hypertension (PH). Using a rat model for monocrotaline-induced PH, we investigated the protective effect of rosuvastatin against IR injury in lungs affected by PH and attempted to elucidate its mechanism of action. METHODS: Male Sprague-Dawley monocrotaline-treated rats were divided into 4 groups (n = 8-9): sham, control + IR, statin + IR, and statin + mevalonolactone + IR. Lung ischemia was induced by left pulmonary artery occlusion (1 hour), followed by reperfusion (4 hours). Rosuvastatin (2 mg/kg) was injected 18 hours before reperfusion and mevalonolactone (1 mg/kg) was injected immediately before reperfusion. The arterial oxygen tension/inspired oxygen fraction ratio was used as a measure of lung oxygenation. Left lung tissue was analyzed for the wet-to-dry lung weight ratio and protein expression of endothelial nitric oxide synthase (eNOS) and phospho-eNOS. Macrophage recruitment was assessed by CD68 immunostaining. RESULTS: Our results showed that rosuvastatin decreased IR lung injury (control + IR vs statin + IR) in terms of the arterial oxygen tension/inspired oxygen fraction ratio (272 ± 43 vs 442 ± 13), wet-to-dry ratio (5.7 ± 0.7 vs 4.8 ± 0.6), and macrophage infiltration (8.0 ± 0.6/field vs 4.0 ± 0.5/field) (P < .05 for all). eNOS and phospho-eNOS were downregulated by IR, which was blocked by rosuvastatin. Effects of rosuvastatin were blunted by mevalonolactone. CONCLUSIONS: Single-dose rosuvastatin decreased IR injury in lungs affected by PH via 2 anti-inflammatory mechanisms: preserving eNOS function and inhibiting macrophage infiltration.
OBJECTIVE: Lung ischemia-reperfusion (IR) injury during cardiopulmonary surgery is associated with postoperative morbidity and mortality, particularly in patients with pulmonary hypertension (PH). Using a rat model for monocrotaline-induced PH, we investigated the protective effect of rosuvastatin against IR injury in lungs affected by PH and attempted to elucidate its mechanism of action. METHODS: Male Sprague-Dawley monocrotaline-treated rats were divided into 4 groups (n = 8-9): sham, control + IR, statin + IR, and statin + mevalonolactone + IR. Lung ischemia was induced by left pulmonary artery occlusion (1 hour), followed by reperfusion (4 hours). Rosuvastatin (2 mg/kg) was injected 18 hours before reperfusion and mevalonolactone (1 mg/kg) was injected immediately before reperfusion. The arterial oxygen tension/inspired oxygen fraction ratio was used as a measure of lung oxygenation. Left lung tissue was analyzed for the wet-to-dry lung weight ratio and protein expression of endothelial nitric oxide synthase (eNOS) and phospho-eNOS. Macrophage recruitment was assessed by CD68 immunostaining. RESULTS: Our results showed that rosuvastatin decreased IR lung injury (control + IR vs statin + IR) in terms of the arterial oxygen tension/inspired oxygen fraction ratio (272 ± 43 vs 442 ± 13), wet-to-dry ratio (5.7 ± 0.7 vs 4.8 ± 0.6), and macrophage infiltration (8.0 ± 0.6/field vs 4.0 ± 0.5/field) (P < .05 for all). eNOS and phospho-eNOS were downregulated by IR, which was blocked by rosuvastatin. Effects of rosuvastatin were blunted by mevalonolactone. CONCLUSIONS: Single-dose rosuvastatin decreased IR injury in lungs affected by PH via 2 anti-inflammatory mechanisms: preserving eNOS function and inhibiting macrophage infiltration.
Authors: Loc V Thang; Stacie L Demel; Robert Crawford; Norbert E Kaminski; Greg M Swain; Nico Van Rooijen; James J Galligan Journal: Am J Physiol Heart Circ Physiol Date: 2015-08-28 Impact factor: 4.733
Authors: Magdalena Rysz-Górzynska; Anna Gluba-Brzózka; Amirhossein Sahebkar; Maria-Corina Serban; Dimitri P Mikhailidis; Sorin Ursoniu; Peter P Toth; Vera Bittner; Gerald F Watts; Gregory Y H Lip; Jacek Rysz; Alberico L Catapano; Maciej Banach Journal: Sci Rep Date: 2016-07-22 Impact factor: 4.379
Authors: Carlos Henrique Marques Dos Santos; Doroty Mesquita Dourado; Baldomero Antonio Kato da Silva; Henrique Budib Dorsa Pontes; Euler de Azevedo Neto; Giovanna Serra da Cruz Vendas; Ian de Oliveira Chaves; João Victor Cunha Miranda; João Victor Durães Gomes Oliva; Letícia do Espírito Santo Dias; Murillo Henrique Martins de Almeida; Trícia Luna Sampaio Journal: Braz J Cardiovasc Surg Date: 2018 Mar-Apr
Authors: Carlos Henrique Marques Dos Santos; Doroty Mesquita Dourado; Baldomero Antonio Kato da Silva; Henrique Budib Dorsa Pontes; Euler de Azevedo-Neto; Giovanna Serra da Cruz Vendas; Ian de Oliveira Chaves; João Victor Cunha Miranda Journal: Arq Bras Cir Dig Date: 2017 Jul-Sep
Authors: Daniel Souza Monteiro de Araújo; Francesco De Logu; Chiara Adembri; Stanislao Rizzo; Malvin N Janal; Lorenzo Landini; Alberto Magi; Gianluca Mattei; Nicoletta Cini; Pablo Pandolfo; Pierangelo Geppetti; Romina Nassini; Karin da Costa Calaza Journal: Cell Death Dis Date: 2020-08-15 Impact factor: 8.469